Equipped with a Master’s degree in Medical Sciences, Oleyna is a fierce advocate known for her drive and tenacity.
Oleyna Strigul
- p.(416) 863-3356
- f.(416) 863-9171
- e.ostrigul@belmorelaw.com
- Bio
- Education
- Affiliations
Oleyna is an associate at Belmore Neidrauer LLP.
She obtained her J.D. degree from Queen’s University in 2021 and was called to the Ontario bar in 2022.
Prior to attending law school, Oleyna completed her M.Sc. in Medical Sciences at McMaster University, specializing in immunology and allergic disease. She was recognized with the Outstanding Achievement Award for her research on cord blood dendritic cell populations in atopic-at-risk and not-at-risk infants.
At Queen’s University Faculty of Law, Oleyna acted as a student caseworker at the Queen’s Business Law Clinic and participated in the Harold G Fox Moot in Intellectual Property, where the Queen’s team took home the prize for Best Respondent Factum. In her spare time, Oleyna acted as President of the Minute Moot Club and created the Queen’s Intellectual Property Law Club, where she also served as President. Following law school, Oleyna articled in an IP boutique in Toronto.
Oleyna attended McMaster University and graduated summa cum laude with a B.Sc (Honours), with distinction, in Life Sciences-Origins Research Specialization.
- Called to the Ontario Bar, 2022
- Queen’s University Faculty of Law, J.D., 2021
- McMaster University, M.Sc. (Medical Sciences), 2018
- McMaster University, B.Sc.H. (Life Sciences-Origins Research Specialization), 2016
- Intellectual Property Institute of Canada
- The Advocates' Society
Related Expertise
Related cases
Related news
-
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court of Appeal rejected Pharmascience’s appeal of the finding of inducement. I... -
Belmore Neidrauer secured another victory in the Federal Court of Appeal for our client Janssen.
On this appeal, the Court affirmed the validity of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court found that the patent claims patentable subject-matter and rejected Pharmascience’s argument that the patent claims an unpatentable method of medica... -
Belmore Neidrauer successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia, this time involving Apotex. The Federal Court of Appeal rejected Apotex’s argument that an inducer’s actions must chan... -
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court of Appeal rejected Pharmascience’s appeal of the finding of inducement. I... -
Belmore Neidrauer secured another victory in the Federal Court of Appeal for our client Janssen.
On this appeal, the Court affirmed the validity of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court found that the patent claims patentable subject-matter and rejected Pharmascience’s argument that the patent claims an unpatentable method of medica... -
Belmore Neidrauer successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia, this time involving Apotex. The Federal Court of Appeal rejected Apotex’s argument that an inducer’s actions must chan... -
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court of Appeal rejected Pharmascience’s appeal of the finding of inducement. I... -
Belmore Neidrauer secured another victory in the Federal Court of Appeal for our client Janssen.
On this appeal, the Court affirmed the validity of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court found that the patent claims patentable subject-matter and rejected Pharmascience’s argument that the patent claims an unpatentable method of medica... -
Belmore Neidrauer successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia, this time involving Apotex. The Federal Court of Appeal rejected Apotex’s argument that an inducer’s actions must chan... -
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court of Appeal rejected Pharmascience’s appeal of the finding of inducement. I... -
Belmore Neidrauer secured another victory in the Federal Court of Appeal for our client Janssen.
On this appeal, the Court affirmed the validity of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court found that the patent claims patentable subject-matter and rejected Pharmascience’s argument that the patent claims an unpatentable method of medica...